Acurx Pharmaceuticals Inc. (ACXP) - מזומנים למניה אחת

Acurx Pharmaceuticals (ACXP) is capturing a niche in innovative treatments for gastrointestinal infections, possessing significant pricing power. Free cash flow per share illustrates this trend, where 1.59 determines this parameter level. Success is based on the registration of ibezapolstat for hospitals, although late-stage trial risks and bacterial resistance create certain uncertainty regarding future revenues.
פילוחים אנליטיים של חברת acurxpharma.com (ACXP)

Cash per share determines the portion of liquid assets attributable to a single security. This metric serves as a tool for monitoring the burn rate in the absence of operating profit. By analyzing cash per share trends, an investor assesses the issuer's runway for viability. For Acurx Pharmaceuticals (ACXP), this indicator is critical, as the company finances antibiotic development through investments. A decline in this metric signals the approaching date when a new funding round will be required.